Combination strategies for checkpoint inhibition: Current practices and perspectives

被引：3
作者：
Dussart, Chloe [1 ]
Decaux-Tramoni, Baptiste [1 ]
Quesada, Stanislas [2 ]
Thomas, Quentin Dominique [1 ,2 ]
Benzerouale, Ouail [1 ]
Nicolas, Emanuel [1 ,3 ]
Fiteni, Frederic [1 ,3 ]
机构：
[1] CHU Nimes, Serv oncol med, 4 rue Prof-Robert-Debre, F-30900 Nimes, France
[2] Inst reg Canc Montpellier, Dept oncol med, F-34298 Montpellier 5, France
[3] Univ Montpellier, Inst Desbrest epidemiol & Sante publ, Inserm UMR 1302, F-34090 Montpellier, France
来源：
BULLETIN DU CANCER | 2023年 / 110卷 / 08期
关键词：
Immune checkpoint; inhibitor; Immunotherapy; Anti-CTLA-4; Anti-PD-1; L1; Anti-LAG-3; CANCER; NIVOLUMAB;
D O I：
10.1016/j.bulcan.2023.03.021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：790 / 801
页数：12
相关论文
共 56 条
  • [1] Abou-Alfa GK, 2022, J CLIN ONCOL, V40
  • [2] Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
    Aggarwal, Charu
    Prawira, Amy
    Antonia, Scott
    Rahma, Osama
    Tolcher, Anthony
    Cohen, Roger B.
    Lou, Yanyan
    Hauke, Ralph
    Vogelzang, Nicholas
    Zandberg, Dan P.
    Kalebasty, Arash Rezazadeh
    Atkinson, Victoria
    Adjei, Alex A.
    Seetharam, Mahesh
    Birnbaum, Ariel
    Weickhardt, Andrew
    Ganju, Vinod
    Joshua, Anthony M.
    Cavallo, Rosetta
    Peng, Linda
    Zhang, Xiaoyu
    Kaul, Sanjeev
    Baughman, Jan
    Bonvini, Ezio
    Moore, Paul A.
    Goldberg, Stacie M.
    Arnaldez, Fernanda, I
    Ferris, Robert L.
    Lakhani, Nehal J.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)
  • [3] MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naive (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial
    Ahn, M-J.
    Kim, S-W.
    Carcereny Costa, E.
    Rodriguez, L. M.
    Oliveira, J.
    Insa Molla, M. A.
    Majem, M.
    Costa, L.
    Su, W-C.
    Lee, K. H.
    Yang, J. C-H.
    Spigel, D. R.
    Cho, E. K.
    D'Arcangelo, M.
    Garcia Campelo, M. R.
    Delmonte, A.
    Mitchell, P.
    Achour, I.
    Subramaniam, D.
    Felip, E.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1423 - S1423
  • [4] Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
    Albiges, Laurence
    Tannir, Nizar M.
    Burotto, Mauricio
    McDermott, David
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Porta, Camillo
    Powles, Thomas
    Donskov, Frede
    George, Saby
    Kollmannsberger, Christian K.
    Gurney, Howard
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Castellano, Daniel
    Rini, Brian, I
    Choueiri, Toni K.
    Saggi, Shruti Shally
    McHenry, M. Brent
    Motzer, Robert J.
    [J]. ESMO OPEN, 2020, 5 (06)
  • [5] Neoadjuvant relatlimab and nivolumab in resectable melanoma
    Amaria, Rodabe N.
    Postow, Michael
    Burton, Elizabeth M.
    Tezlaff, Michael T.
    Ross, Merrick, I
    Torres-Cabala, Carlos
    Glitza, Isabella C.
    Duan, Fei
    Milton, Denai R.
    Busam, Klaus
    Simpson, Lauren
    McQuade, Jennifer L.
    Wong, Michael K.
    Gershenwald, Jeffrey E.
    Lee, Jeffrey E.
    Goepfert, Ryan P.
    Keung, Emily Z.
    Fisher, Sarah B.
    Betof-Warner, Allison
    Shoushtari, Alexander N.
    Callahan, Margaret
    Coit, Daniel
    Bartlett, Edmund K.
    Bello, Danielle
    Momtaz, Parisa
    Nicholas, Courtney
    Gu, Aidi
    Zhang, Xuejun
    Korivi, Brinda Rao
    Patnana, Madhavi
    Patel, Sapna P.
    Diab, Adi
    Lucci, Anthony
    Prieto, Victor G.
    Davies, Michael A.
    Allison, James P.
    Sharma, Padmanee
    Wargo, Jennifer A.
    Ariyan, Charlotte
    Tawbi, Hussein A.
    [J]. NATURE, 2022, 611 (7934) : 155 - +
  • [6] Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
    Anderson, Ana C.
    Joller, Nicole
    Kuchroo, Vijay K.
    [J]. IMMUNITY, 2016, 44 (05) : 989 - 1004
  • [7] Andrz T, 2022, ANN ONCOL, V33
  • [8] [Anonymous], 1990, J EXP MED, V171
  • [9] First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
    Baas, Paul
    Scherpereel, Arnaud
    Nowak, Anna K.
    Fujimoto, Nobukazu
    Peters, Solange
    Tsao, Anne S.
    Mansfield, Aaron S.
    Popat, Sanjay
    Jahan, Thierry
    Antonia, Scott
    Oulkhouir, Youssef
    Bautista, Yolanda
    Cornelissen, Robin
    Greillier, Laurent
    Grossi, Francesco
    Kowalski, Dariusz
    Rodriguez-Cid, Jeronimo
    Aanur, Praveen
    Oukessou, Abderrahim
    Baudelet, Christine
    Zalcman, Gerard
    [J]. LANCET, 2021, 397 (10272) : 375 - 386
  • [10] Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
    Bagchi, Sreya
    Yuan, Robert
    Engleman, Edgar G.
    [J]. ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021, 2021, 16 : 223 - 249
123456